These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 23144930)
1. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. Jonsdottir K; Janssen SR; Da Rosa FC; Gudlaugsson E; Skaland I; Baak JP; Janssen EA PLoS One; 2012; 7(11):e48692. PubMed ID: 23144930 [TBL] [Abstract][Full Text] [Related]
2. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Janssen EA; Slewa A; Gudlaugsson E; Jonsdottir K; Skaland I; Søiland H; Baak JP Mod Pathol; 2010 Dec; 23(12):1567-76. PubMed ID: 20818337 [TBL] [Abstract][Full Text] [Related]
3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study. Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940 [TBL] [Abstract][Full Text] [Related]
4. MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers. Egeland NG; Jonsdottir K; Aure MR; Sahlberg K; Kristensen VN; Cronin-Fenton D; Skaland I; Gudlaugsson E; Baak JPA; Janssen EAM BMC Cancer; 2020 May; 20(1):377. PubMed ID: 32370743 [TBL] [Abstract][Full Text] [Related]
5. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482 [TBL] [Abstract][Full Text] [Related]
6. Associations of high expression of miR-106b-5p detected from FFPE sample with poor prognosis of RCC patients. Liu K; Pan X; Peng X; Zhang C; Li H; Guan X; Xu W; Xu J; Zhao L; Wang T; Lai Y Pathol Res Pract; 2019 Jun; 215(6):152391. PubMed ID: 31076282 [TBL] [Abstract][Full Text] [Related]
7. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831 [TBL] [Abstract][Full Text] [Related]
8. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649 [TBL] [Abstract][Full Text] [Related]
9. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. Wang B; Li J; Sun M; Sun L; Zhang X IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313 [TBL] [Abstract][Full Text] [Related]
10. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. Quesne JL; Jones J; Warren J; Dawson SJ; Ali HR; Bardwell H; Blows F; Pharoah P; Caldas C J Pathol; 2012 Jul; 227(3):306-14. PubMed ID: 22294324 [TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208 [TBL] [Abstract][Full Text] [Related]
12. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881 [TBL] [Abstract][Full Text] [Related]
13. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Foekens JA; Sieuwerts AM; Smid M; Look MP; de Weerd V; Boersma AW; Klijn JG; Wiemer EA; Martens JW Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13021-6. PubMed ID: 18755890 [TBL] [Abstract][Full Text] [Related]
14. Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis. Ahmadinejad F; Mowla SJ; Honardoost MA; Arjenaki MG; Moazeni-Bistgani M; Kheiri S; Teimori H Tumour Biol; 2017 Aug; 39(8):1010428317698362. PubMed ID: 28857013 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954 [TBL] [Abstract][Full Text] [Related]
16. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561 [TBL] [Abstract][Full Text] [Related]
17. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer. Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574 [TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer. Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524 [TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA). Kim SY; Kawaguchi T; Yan L; Young J; Qi Q; Takabe K Ann Surg Oncol; 2017 Oct; 24(10):2943-2949. PubMed ID: 28766230 [TBL] [Abstract][Full Text] [Related]
20. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]